Executive perspectives: Bruno Strigini

Paul Tunnah interviews Bruno Strigini

President, Europe/Canada at MSD

Continuing our series of senior level interviews, pharmaphorum speaks with Bruno Strigini, President of Europe/ Canada for MSD, to hear his views on why Europe remains competitive in the global pharma market and how MSD, known as Merck in the United States and Canada, is rising to the challenges of healthcare cost containment whilst still delivering innovation.

As the pharma industry faces a number of challenges to maintaining growth rates, particularly in Western markets, it seeks to embrace the globalised nature of its business and the opportunities afforded by the emerging markets. However, within this context, maintaining a strong presence within its core developed markets, such as Europe, with regards to both drug development and commercialisation is a critical factor in ensuring the continued long-term success in bringing new medicines to market.

To better understand the evolving role for Europe within this global environment and how pharma can continue to deliver innovation in regions facing stringent healthcare cost containment, pharmaphorum caught up with Bruno Strigini, President of Europe/Canada for MSD.

During this video interview, we explore how the focus on value is addressed by MSD across the diverse local landscapes within Europe and how excessive cost containment could impact innovation and early drug development. In addition, Bruno elaborates on how Europe can remain competitive on the global pharma landscape, the importance of successful collaboration between industry, academia and healthcare providers and how MSD is adapting its business for onward success.

To watch the full interview, please click on the play button below.


0:15 – Communicating medicines’ value across a diverse European region

2:10 – How is healthcare cost containment impacting early drug development?

3:08 – Maintaining a competitive environment for Europe within global pharma

5:35 – Key aspects to successful public-private partnerships

6:37 – How is MSD adapting to the challenges currently facing the pharma industry?

Subscribe to pharmaphorum on YouTube to be the first to hear about new videos – http://www.youtube.com/pharmaphorum.


About the interviewee:

Bruno Strigini is President of Europe/Canada for Merck &amp, Co., Inc., known as MSD outside the United States and Canada. Strigini has dedicated his entire career to healthcare and is a business leader with a strong international experience and perspective in the global healthcare industry. He has held increasingly senior executive positions in a number of companies, including Schering-Plough, UCB-Celltech and SmithKline Beecham, and has been responsible for leading a diverse range of markets and regions around the world.

During his career, Strigini has led various functions, ranging from strategy and operations, to global marketing and business development. He is a board member for Intervet, a global leader in the research, development, manufacturing and sale of veterinary medicines. He is also a member of the Executive Committee for the European Federation of Pharmaceutical Industries &amp, Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France. Strigini holds an MBA from IMD, Lausanne (Switzerland), a doctorate degree in pharmacy from the University of Montpellier (France), and a master’s degree in microbiology from Heriot-Watt University (UK).

What is Europe’s future in the global pharma industry?